Corcept Therapeutics (CORT) CSO Hazel Hunt awarded 140,000 stock options

Rhea-AI Filing Summary

Corcept Therapeutics reported that Chief Scientific Officer Hazel Hunt received a grant of stock options. The award covers 140,000 stock options with a stated exercise price of $0.00 per share, reflecting a compensatory equity grant rather than an open-market purchase.

These options begin vesting from February 27, 2026 and will vest in equal installments on each monthly anniversary of that date over a four-year period. Vesting is conditioned on Hunt’s continued service through each vesting date, tying the award to long-term employment and performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hunt Hazel

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	140,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 140,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hunt Hazel

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$35.7	02/27/2026		A		140,000		(1)	02/27/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Hazel Hunt	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Corcept Therapeutics (CORT) disclose about Hazel Hunt in this Form 4?

Corcept Therapeutics disclosed that Chief Scientific Officer Hazel Hunt received a grant of 140,000 stock options. The options were awarded at a stated exercise price of $0.00 per share and are structured as part of her equity compensation package.

How many stock options did Hazel Hunt receive from Corcept Therapeutics (CORT)?

Hazel Hunt received 140,000 stock options from Corcept Therapeutics. This entire amount is reported as beneficially owned following the transaction, indicating it is a new equity award rather than a partial adjustment to an existing option position.

What is the exercise price of Hazel Hunt’s Corcept Therapeutics (CORT) stock options?

The reported exercise price of Hazel Hunt’s stock options is $0.00 per share. This structure is typical for certain compensatory grants, making the economic value dependent on the company’s share price performance and the continued vesting of the award over time.

How do Hazel Hunt’s Corcept Therapeutics (CORT) options vest over time?

Hazel Hunt’s options vest in equal installments on each monthly anniversary of February 27, 2026, over a four-year period. Vesting is contingent on her continued service through each vesting date, aligning the award with long-term retention and ongoing employment at Corcept Therapeutics.

Is Hazel Hunt’s Form 4 transaction a purchase or a grant of CORT securities?

Hazel Hunt’s Form 4 transaction reflects a grant or award acquisition of derivative securities, not an open-market purchase. The filing classifies the transaction under code A, meaning a compensatory grant of stock options rather than a buy or sell in the public market.

Does Hazel Hunt hold the Corcept Therapeutics (CORT) options directly or indirectly?

The Form 4 indicates Hazel Hunt holds the 140,000 stock options directly. The ownership code is reported as direct, and there is no footnote describing any trust, LLC, or third-party entity holding voting or investment power over these derivative securities.